Watchlist

Watchlist
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)
Your Daily Pharma Scoop: Valeant's B+L In India, TXMD's NDA Resubmission, Melinta Makes An Acquisition
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant B+L This is a tidy little art…
Aldeyra's ADX-102 on par with steroid eye drop in mid-stage uveitis study; shares down 2%
New analyses of a Phase 2 clinical trial evaluating Aldeyra Therapeutics' ( ALDX -1.5% ) topical reproxalap (formerly ADX-102) in patients with noninfectious anterior uveitis showed it to be non-inferior (no worse than) to Pred Forte (prednisone acetate), a topical steroid for ophthal…
Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
LEXINGTON, Mass. , Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistic…
Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript
Aldeyra Therapeutics, Inc. (ALDX) Q3 2017 Earnings Conference Call November 9, 2017 8:00 AM ET Executives Steve Tulipano Chief Financial Officer Todd Brady President and Chief Executive Officer Analysts Neil Carnahan Stifel Nicolaus Yale Jen &#x20…
Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results
LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to…
Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference
LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, to…
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results
LEXINGTON, Mass. , Nov.2, 2017 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it…
Premarket Gainers as of 9:05 am
MGNX +36% on entering into an exclusive global collaboration and license agreement withIncyte (NASDAQ: INCY )for MacroGenics MGA012. More news on: MacroGenics, Inc., Incyte Corporation, Capricor Therapeutics, Inc., Stocks on the move, Read more …
Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
LEXINGTON, Mass. , Oct. 25, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will p…
Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting
LEXINGTON, Mass. , Oct. 24, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc.(NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented novel data…
Aldeyra Therapeutics (ALDX) Investor Presentation - Slideshow
The following slide deck was published by Aldeyra Therapeutics, Inc. in conjunction with this Read more …
Aldeyra Therapeutics, Inc. (ALDX)